Pfizer's new anti-infection innovative drug approved for pediatric use

The Pfizer innovative drug Isavuconazonium sulfate capsules for anti-infection has been approved in China for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric patients aged 6 to 18 years old with a body weight 16 kg.